Obicetrapib exhibits favorable physiochemical and pharmacokinetic properties compared to previous cholesteryl ester transfer protein inhibitors: An integrated summary of results from non‐human primate studies and clinical trials

Obicetrapib exhibits favorable physiochemical and pharmacokinetic properties compared to previous cholesteryl ester transfer protein inhibitors: An integrated summary of results from non‐human primate studies and clinical trials

Abstract Anacetrapib, a cholesteryl ester transfer protein (CETP) inhibitor previously under development, exhibited an usually extended terminal half‐life and large food effect and accumulated in adipose tissue. Other CETP inhibitors have not shown such effects. Obicetrapib, a potent selective CETP...

Full description

Saved in:
Bibliographic Details
Main Authors: Stephen J. Nicholls, Adam J. Nelson, John J. P. Kastelein, Marc Ditmarsch, Andrew Hsieh, Judith Johnson, Danielle Curcio, Douglas Kling, Carol F. Kirkpatrick, Michael H. Davidson
Format: Article
Language:English
Published: Wiley 2024-12-01
Series:Pharmacology Research & Perspectives
Subjects:
accumulation
anacetrapib
cholesteryl ester transfer protein
elimination
obicetrapib
pharmacokinetics
Online Access:https://doi.org/10.1002/prp2.70010
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items